Vineet Sankhla/X
Sep 8, 2026, 09:42
Vineet Sankhla: Rethinking Potent P2Y12 Inhibition in AF Patients Undergoing PCI
Vineet Sankhla, Interventional Cardiologist Health New Zealand – Te Whatu Ora, shared a post on X:
“More bleeding with Prasu/Tica plus DOACs in AF patients undergoing PCI.
Clopidogrel may be safer choice in triple anti platelet therapy.
EPIDAURUS: Escalated single platelet inhibition for one month plus direct oral anticoagulation in patients with atrial fibrillation and ACS undergoing PCI.”
Stay updated with Hemostasis Today.
-
Oct 10, 2026, 00:34Raphaëlle Dodart: Discussing the Mechanisms of Menstrual Hemostasis
-
Oct 10, 2026, 00:26Barbara Adams Krolak: Discussing the Growing Need for Blood Clot Prevention in Asia
-
Oct 9, 2026, 23:59Ana Pedrero Gil: Is Coagulopathy with Fibrinolysis Present in All Obstetric Hemorrhages?
-
Oct 9, 2026, 23:57Exploring the Psychosocial Needs of People with Bleeding Disorders in Kyrgyzstan – EAHAD
-
Oct 9, 2026, 23:53Bernard Slater Jr.: Serving on the Advisory Council for the NBDF West Virginia Chapter
-
Oct 9, 2026, 23:53Aurelio Maggio: Thalassemia Reports Real-Time Impact Factor Rises to 1.760
-
Oct 9, 2026, 23:52Stronger Connections, Stronger Organizations – World Federation of Hemophilia
-
Oct 9, 2026, 23:46Samuel Misiani Mbunya: Advancing Sickle Cell Care Through Collaboration at the 21st ASCAT Conference
-
Oct 9, 2026, 23:42Hadeel Swed: My First First-Author Publication in Thrombosis Research